Drug intelligence / Profile preview

OA-SYS

Development stage: Phase 2
Lead developer: Ageless Biotech
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

OA-SYS is an investigational stem cell therapy developed for the treatment of osteoarthritis, specifically targeting knee osteoarthritis. The drug is being developed by Ageless Biotech and has reached Phase 2 clinical trials. Its primary therapeutic area is skin and musculoskeletal diseases, with a focus on providing regenerative treatment for degenerative joint conditions such as osteoarthritis of the knee. The mechanism of action likely involves the use of stem cells to promote tissue repair and modulate inflammation within the affected joint, although specific molecular targets have not been detailed in public sources[1][3].

Other names: Ageless Biotech stromal vascular fractionSVFstromal vascular fraction

Beyond the preview

Go deeper on OA-SYS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OA-SYS.

Explore the full profile